Yoichi Aoki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoichi Aoki has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Kenichi Tanaka
18 shared publicationsMinoru Watanabe
6 shared publicationsHiroaki Kase
Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi dori Niigata 951-8510, Japan
4 shared publicationsHiroshi Aida
Department of Obstetrics and Gynecology, Niigata University Faculty of Medicine, Niigata, Japan
4 shared publicationsIkunosuke Tsuneki
From the Department of Obstetrics and Gynecology, Faculty of Medicine, Niigata University, Japan
4 shared publicationsK. Tanaka
Division of Molecular Genetics, Department of Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
4 shared publications
Latest Publications
- 31 August 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 391-393
Retrieval of intraperitoneal Penrose drain under transvaginal endoscopic guidance
- 31 August 2006
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 391-393
Retrieval of intraperitoneal Penrose drain under transvaginal endoscopic guidance
- 1 November 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 99 (2) , 497-499
Yolk sac tumor of the ovary during pregnancy: A case report
- 1 November 2005
- Published by Elsevier in Gynecologic Oncology
- Vol. 99 (2) , 497-499
Yolk sac tumor of the ovary during pregnancy: A case report
- 1 March 2005
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 15 (2) , 385-388
Placental site trophoblastic tumor presenting as subaponeurotic metastasis
- 1 March 2005
- Published by Elsevier in International Journal of Gynecological Cancer
- Vol. 15 (2) , 385-388
Placental site trophoblastic tumor presenting as subaponeurotic metastasis
- 1 October 2004
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 27 (5) , 461-464
Combination Chemotherapy With Irinotecan Hydrochloride (CPT-11) and Mitomycin C in Platinum-Refractory Ovarian Cancer
The aim of this study was to examine the level of activity of irinotecan hydrochloride (CPT-11) and mitomycin-C (MMC) combination chemotherapy in a patient population with platinum-refractory ovarian cancer. Patients received CPT-11 (140 mg/m2) in combination with MMC (7 mg/m2) on days 1, 15, 29 until disease progression, unacceptable toxicity developed, or they elected to discontinue treatment. Overall, 61 cycles of CPT-11/MMC chemotherapy were delivered to 13 patients. The major toxicity with this regimen was neutropenia, which was brief and reversible. The incidences of grade 3 and 4 neutropenia were 46% (6/13) and 15% (2/13), respectively. The nonhematological toxicities were generally mild and well tolerated. Of the 13 patients, 4 (31%) experienced an objective response (1 CR, 3 PRs). Among responders, the median duration of response was 30 weeks (range, 12 to 292+ weeks). The median time to progression for the 13 patients who received treatment on this trial was 24 weeks (range, 8 to 292+ weeks), with a median survival of 36 weeks (range, 20 to 292+ weeks). This preliminary study shows that the combination of CPT-11 and MMC appears to be an active regimen in patients with refractory ovarian cancer.
- 1 October 2004
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 27 (5) , 461-464
Combination Chemotherapy With Irinotecan Hydrochloride (CPT-11) and Mitomycin C in Platinum-Refractory Ovarian Cancer
The aim of this study was to examine the level of activity of irinotecan hydrochloride (CPT-11) and mitomycin-C (MMC) combination chemotherapy in a patient population with platinum-refractory ovarian cancer. Patients received CPT-11 (140 mg/m2) in combination with MMC (7 mg/m2) on days 1, 15, 29 until disease progression, unacceptable toxicity developed, or they elected to discontinue treatment. Overall, 61 cycles of CPT-11/MMC chemotherapy were delivered to 13 patients. The major toxicity with this regimen was neutropenia, which was brief and reversible. The incidences of grade 3 and 4 neutropenia were 46% (6/13) and 15% (2/13), respectively. The nonhematological toxicities were generally mild and well tolerated. Of the 13 patients, 4 (31%) experienced an objective response (1 CR, 3 PRs). Among responders, the median duration of response was 30 weeks (range, 12 to 292+ weeks). The median time to progression for the 13 patients who received treatment on this trial was 24 weeks (range, 8 to 292+ weeks), with a median survival of 36 weeks (range, 20 to 292+ weeks). This preliminary study shows that the combination of CPT-11 and MMC appears to be an active regimen in patients with refractory ovarian cancer.
- 1 August 2004
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (2) , 333-339
Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer
- 1 August 2004
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (2) , 333-339
Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer
- 21 February 2004
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 10 (2) , 148-151
Stage IVa squamous cell carcinoma of the vulva managed with primary chemoradiation
We present the case of a 53-year-old woman with International Federation of Gynecology and Obstetrics stage IVa (T3N2M0) squamous cell carcinoma of the vulva. Because the urethra was surrounded by a vulvar tumor, she was managed with primary chemoradiation in an attempt to spare the morbidity associated with exenterative vulvar surgery. Treatment was given as a planned split course, consisting of two separate courses of 23.8 Gy each. During each split course of radiation, 5-fluorouracil, 1000 mg/m2 per day, was given over the first 4 days, and cisplatin 50 mg/m2 was administered as a single infusion on the first day. During the 4 days of chemotherapy infusion, the radiation was administered in two daily fractions of 1.7 Gy each, given at least 6 h apart. There was no treatment break due to adverse effect, and a pathological complete response was achieved in the primary tumor and the lymph nodes. The patient did not undergo surgical intervention, and has had no evidence of recurrence for 24 months. Chemoradiation therapy should be considered as an option in patients with locally advanced vulvar cancer to avert the need for exenterative surgery, and to preserve sexual, gastrointestinal, and urinary function.
- 21 February 2004
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 10 (2) , 148-151
Stage IVa squamous cell carcinoma of the vulva managed with primary chemoradiation
We present the case of a 53-year-old woman with International Federation of Gynecology and Obstetrics stage IVa (T3N2M0) squamous cell carcinoma of the vulva. Because the urethra was surrounded by a vulvar tumor, she was managed with primary chemoradiation in an attempt to spare the morbidity associated with exenterative vulvar surgery. Treatment was given as a planned split course, consisting of two separate courses of 23.8 Gy each. During each split course of radiation, 5-fluorouracil, 1000 mg/m2 per day, was given over the first 4 days, and cisplatin 50 mg/m2 was administered as a single infusion on the first day. During the 4 days of chemotherapy infusion, the radiation was administered in two daily fractions of 1.7 Gy each, given at least 6 h apart. There was no treatment break due to adverse effect, and a pathological complete response was achieved in the primary tumor and the lymph nodes. The patient did not undergo surgical intervention, and has had no evidence of recurrence for 24 months. Chemoradiation therapy should be considered as an option in patients with locally advanced vulvar cancer to avert the need for exenterative surgery, and to preserve sexual, gastrointestinal, and urinary function.
- 1 August 2003
- Vol. 48 (8) , 659-60
Delayed, massive bleeding as an unusual complication of laser conization. A case report.
Although delayed bleeding following cervical conization is a common complication of this surgical procedure, the amount of blood loss is usually not life threatening. A 27-year-old woman underwent conization with a KTP laser for the treatment of microinvasive cervical adenocarcinoma. Eight days later the patient experienced sudden, massive genital bleeding at her workplace. The source of the bleeding was identified as a descending branch of the left uterine artery exposed to the wound surface. Hemostasis was achieved completely with direct surgical ligature of the exposed blood vessel. The patient's blood loss during the course of the events was estimated to be 3.2 L, for which she received 1.4 L of packed red blood cells. She had an uneventful postoperative recovery. There was no bleeding or recurrence of the disease during 4 years of follow-up. Clinicians should be alert to the possibility of massive bleeding as a delayed surgical complication of cervical conization.
- 1 August 2003
- Vol. 48 (8) , 659-60
Delayed, massive bleeding as an unusual complication of laser conization. A case report.
Although delayed bleeding following cervical conization is a common complication of this surgical procedure, the amount of blood loss is usually not life threatening. A 27-year-old woman underwent conization with a KTP laser for the treatment of microinvasive cervical adenocarcinoma. Eight days later the patient experienced sudden, massive genital bleeding at her workplace. The source of the bleeding was identified as a descending branch of the left uterine artery exposed to the wound surface. Hemostasis was achieved completely with direct surgical ligature of the exposed blood vessel. The patient's blood loss during the course of the events was estimated to be 3.2 L, for which she received 1.4 L of packed red blood cells. She had an uneventful postoperative recovery. There was no bleeding or recurrence of the disease during 4 years of follow-up. Clinicians should be alert to the possibility of massive bleeding as a delayed surgical complication of cervical conization.
- 31 July 2003
- Published by Elsevier in Gynecologic Oncology
- Vol. 90 (1) , 70-74
Fas ligand expression in cervical adenocarcinoma: Relevance to lymph node metastasis and tumor progression
- 31 July 2003
- Published by Elsevier in Gynecologic Oncology
- Vol. 90 (1) , 70-74
Fas ligand expression in cervical adenocarcinoma: Relevance to lymph node metastasis and tumor progression
- 1 March 2003
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 55 (1) , 58-60
Dysgerminoma with a Slightly Elevated α-Fetoprotein Level Diagnosed as a Mixed Germ Cell Tumor after Recurrence
A pure dysgerminoma shows a normal serum α-fetoprotein level, and mixed germ cell tumors containing endodermal sinus tumor elements have elevated serum α-fetoprotein levels, ranging from >100 to far higher than 1,000 ng/ml. A 40-year-old woman was diagnosed as having a stage Ia pure dysgerminoma with a slight α-fetoprotein elevation (11 ng/ml), after a staging laparotomy, because we could not find any yolk sac element in the original tumor. After 44 months, she had a pelvic recurrent tumor with a significant elevation of the serum α-fetoprotein concentration (1,520 ng/ml); histological examination of a needle biopsy specimen revealed a typical yolk sac tumor. Eventually, her initial tumor was diagnosed as a mixed germ cell tumor. The patient was successfully treated with seven courses of chemotherapy and has been disease free for 22 months. It is necessary to be aware of the possibility of a mixed germ cell tumor containing a yolk sac element, even when the α-fetoprotein level is only slightly elevated.
- 1 March 2003
- Published by S. Karger AG in Gynecologic and Obstetric Investigation
- Vol. 55 (1) , 58-60
Dysgerminoma with a Slightly Elevated α-Fetoprotein Level Diagnosed as a Mixed Germ Cell Tumor after Recurrence
A pure dysgerminoma shows a normal serum α-fetoprotein level, and mixed germ cell tumors containing endodermal sinus tumor elements have elevated serum α-fetoprotein levels, ranging from >100 to far higher than 1,000 ng/ml. A 40-year-old woman was diagnosed as having a stage Ia pure dysgerminoma with a slight α-fetoprotein elevation (11 ng/ml), after a staging laparotomy, because we could not find any yolk sac element in the original tumor. After 44 months, she had a pelvic recurrent tumor with a significant elevation of the serum α-fetoprotein concentration (1,520 ng/ml); histological examination of a needle biopsy specimen revealed a typical yolk sac tumor. Eventually, her initial tumor was diagnosed as a mixed germ cell tumor. The patient was successfully treated with seven courses of chemotherapy and has been disease free for 22 months. It is necessary to be aware of the possibility of a mixed germ cell tumor containing a yolk sac element, even when the α-fetoprotein level is only slightly elevated.
- 1 February 2003
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 8 (1) , 53-55
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer
- 1 February 2003
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 8 (1) , 53-55
Docetaxel and carboplatin combination chemotherapy for recurrent endometrial cancer